Supplementary Figure 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma
Key Points
Key points are not available for this paper at this time.
Abstract
This figure entails the selection of HNSCC and LUSC PDX model based on the H-score of EGFR and MET.
Supplementary Figure 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma | Synapse